Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinsonâs disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).

Employees

443

Sector

Biotechnology & Medical Research

Calendar

07-28 - BTIG Virtual Biotechnology Conference

More about the company

Quotes

Date	Price	Change	Volume
25-06-13	14.48 $	-2.95%	1,340,270
25-06-12	14.92 $	-1.74%	1,935,800
25-06-11	15.19 $	-0.46%	1,180,641
25-06-10	15.26 $	+4.20%	1,861,411
25-06-09	14.64 $	-0.37%	1,098,572

Delayed Quote Nasdaq, June 13, 2025 at 03:39 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.92USD

Average target price

32.19USD

Spread / Average Target

+115.66%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 15:54:40 2025-06-13 EDT			5-day change	1st Jan Change
14.42 ^USD	-3.42%		-1.43%	-28.90%

06-03	Denali Therapeutics Inc. Elects Julian Baker as Class II Director	CI
05-13	Denali Therapeutics Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 02:20 PM

Capitalization	2.17B 1.88B 1.76B 1.6B 2.94B 187B 3.33B 20.57B 8B 85.46B 8.14B 7.96B 312B	P/E ratio 2025 *	-5x	P/E ratio 2026 *	-5.42x
Enterprise value	1.51B 1.31B 1.23B 1.11B 2.06B 130B 2.33B 14.36B 5.59B 59.67B 5.68B 5.56B 218B	EV / Sales 2025 *	73.4x	EV / Sales 2026 *	15x
Free-Float	90.34%	Yield 2025 *	-	Yield 2026 *	-

Denali Therapeutics Inc. Elects Julian Baker as Class II Director	06-03	CI
Denali Therapeutics Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 02:20 PM	05-13
B. Riley Adjusts Denali Therapeutics Price Target to $30 From $35, Maintains Buy Rating	05-08	MT
Deutsche Bank Adjusts Denali Therapeutics Price Target to $28 From $29, Maintains Buy Rating	05-08	MT
Denali Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-06	CI
Top Premarket Decliners	04-23	MT
Sector Update: Health Care Stocks Advance in Late Afternoon Trading	04-02	MT
Sector Update: Health Care	04-02	MT
Denali Therapeutics Files Application for Accelerated Approval of Hunter Syndrome Treatment; Shares Up	04-02	MT
Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome	04-02	RE
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through Start Program	04-02	CI
Denali Therapeutics Inc. Presents at UBS Virtual CNS Day 2025, Mar-17-2025 12:00 PM	03-17
Denali Therapeutics Inc To Discontinue Active Treatment Extension In Regimen G	03-05	RE

B. Riley Adjusts Denali Therapeutics Price Target to $30 From $35, Maintains Buy Rating	05-08	MT
Deutsche Bank Adjusts Denali Therapeutics Price Target to $28 From $29, Maintains Buy Rating	05-08	MT
B. Riley Trims Price Target on Denali Therapeutics to $35 From $38, Keeps Buy Rating	03-05	MT
Oppenheimer Adjusts Denali Therapeutics Price Target to $42 From $50, Maintains Outperform Rating	03-03	MT
Deutsche Bank Adjusts Denali Therapeutics Price Target to $29 From $31, Maintains Buy Rating	03-03	MT

Denali Therapeutics Inc. Stock

Equities

DNLI

US24823R1059

Biotechnology & Medical Research

Valuation: Denali Therapeutics Inc.

Chart: Denali Therapeutics Inc.

Latest news: Denali Therapeutics Inc.

Last Transcript: Denali Therapeutics Inc.

Analysts' recommendations: Denali Therapeutics Inc.

Press Releases: Denali Therapeutics Inc.

News in other languages: Denali Therapeutics Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Denali Therapeutics Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome	05-06	GL
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome and Positive Ongoing Interactions with FDA on DNL126 through START Program	04-03	AQ
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program	04-02	GL
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program	04-02	AQ
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights	02-27	GL

Sanofi : échec d'un essai de phase 2 contre la SLA	24-02-16
Pfizer y Flagship Pioneering invertirán 100 millones de dólares en el descubrimiento de fármacos	23-07-18
Biogen : remanie son programme contre la maladie de Parkison	23-06-05
En medio de la suspensión de la FDA, Denali pone en marcha un estudio sobre el Alzheimer en Europa -- Market Talk	22-07-05

1 day	-3.12%
1 week	-1.43%
Current month	+9.44%
1 month	+1.61%
3 months	-2.69%
6 months	-36.92%
Current year	-28.90%

1 week	14.19	15.69
1 month	12.86	15.69
Current year	10.57	24.34
1 year	10.57	33.33
3 years	10.57	39.43
5 years	10.57	93.94
10 years	10.57	93.94

Manager	Title	Age	Since
Alexander Schuth DFI	Director of Finance/CFO	51	2022-04-30
Ryan Watts CEO	Chief Executive Officer	49	2015-07-31
Joe Lewcock CTO	Chief Tech/Sci/R&D Officer	-	2019-12-31

Director	Title	Age	Since
Ryan Watts BRD	Director/Board Member	49	2015-02-28
Marc Tessier-Lavigne CHM	Chairman	65	2015-02-28
Jay Flatley BRD	Director/Board Member	72	2015-03-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
DENALI THERAPEUTICS INC.	-3.58%	-1.43%	-34.49%	-34.32%	2.17B
REGENERON PHARMACEUTICALS, INC.	+1.23%	+7.27%	-48.46%	-3.68%	55.14B
ARGENX SE	-0.63%	-2.63%	+40.16%	+62.08%	35.75B
BEONE MEDICINES LTD.	-2.33%	+5.37%	+62.04%	+106.91%	35.24B
WUXI APPTEC CO., LTD.	+0.83%	+5.88%	+50.44%	-33.61%	27.19B
BIONTECH SE	+1.23%	-2.30%	+10.42%	-20.67%	25.22B
INSMED INCORPORATED	+1.23%	+35.03%	+61.30%	+471.98%	18.4B
SUMMIT THERAPEUTICS INC.	-1.51%	-4.03%	+144.25%	+2,014.50%	14.97B
GENMAB A/S	-0.20%	+2.46%	-18.80%	-25.54%	14.18B
WUXI BIOLOGICS (CAYMAN) INC.	+0.90%	+12.45%	+123.29%	-59.42%	14.38B
Average	-0.23%	+7.02%	+39.01%	+247.82%	24.26B
Weighted average by Cap.	+0.10%	+6.45%	+30.10%	+172.70%

	2025 *	2026 *
Net sales	20.63M 17.85M 16.75M 15.18M 28.02M 1.78B 31.7M 196M 76.18M 813M 77.45M 75.78M 2.97B	109M 94.59M 88.75M 80.43M 148M 9.41B 168M 1.04B 404M 4.31B 410M 402M 15.74B
Net income	-527M -456M -428M -388M -716M -45.38B -810M -5B -1.95B -20.77B -1.98B -1.94B -75.89B	-505M -437M -410M -372M -686M -43.5B -776M -4.79B -1.87B -19.91B -1.9B -1.86B -72.75B
Net Debt	-654M -566M -531M -481M -889M -56.35B -1.01B -6.21B -2.42B -25.79B -2.46B -2.4B -94.23B	-528M -457M -429M -388M -717M -45.45B -811M -5.01B -1.95B -20.81B -1.98B -1.94B -76.01B